FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							` '				. ,							
1. Name and Address of Reporting Person* <u>Dunsire Deborah</u>					2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
													X Direct	or		10% Ov	vner	
(Last)	`	rst) X PHARMACE	(Middle)	INC		3. Date of Earliest Transaction (Month/Day/Year) 06/22/2017								Officer (give title Other (specify below) below)				specify
			UTICAL	IIVC.														
60 LEVERONI COURT						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)		Δ.	0.40.40											X Form	•		orting Perso	
NOVATO	O C.	A	94949		_								Form filed by More than One Reporting Person					
(City)	(Si	tate)	(Zip)															
		Tab	le I - No	n-Deriv	/ative	Se	curitie	s Ac	quired,	Dis	posed o	of, or Be	neficia	ly Owne	t			
1. Title of Security (Instr. 3)  2. Tran Date (Month			ction 2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		Dispose	rities Acquired (A) o ed Of (D) (Instr. 3, 4 a		Benefic	ies For cially (D) Following (I) (I ed ction(s)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v			Amount		(A) or (D) Pri		Transac (Instr. 3	
Common Stock 06/22/2				2/2017	2017		A		1,875 <sup>(1)</sup> A		\$0.0	0 1,	1,875		D			
		T										, or Ben ble sec		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transaction Code (Instr 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactic (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	Code	v	(A)	(D)	Date Exercisab		xpiration late	Title	Amount or Number of Shares					
Employee Stock Option (Right to	\$65.66	06/22/2017			A		3,750		(2)	0	6/22/2027	Common Stock	3,750	\$0.00	3,750	)	D	

## Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018.

## Remarks:

/s/ Ruben A. Garcia, attorneyin-fact

06/22/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.